Iranian Research Center for HIV/AIDS, Iranian Institute for Reduction of High Risk Behaviors, Tehran University of Medical Sciences, Tehran, Iran.
Department of Global Health and Socioepidemiology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Eur J Med Res. 2021 Jun 8;26(1):51. doi: 10.1186/s40001-021-00524-8.
Coronavirus Disease-2019 (SARS-CoV-2) started its devastating trajectory into a global pandemic in Wuhan, China, in December 2019. Ever since, several variants of SARS-CoV-2 have been identified. In the present review, we aimed to characterize the different variants of SARS-CoV-2 and explore the related morbidity and mortality.
A systematic review including the current evidence related to different variants of SARS-CoV-2 and the related morbidity and mortality was conducted through a systematic search utilizing the keywords in the online databases including Scopus, PubMed, Web of Science, and Science Direct; we retrieved all related papers and reports published in English from December 2019 to September 2020.
A review of identified articles has shown three main genomic variants, including type A, type B, and type C. we also identified three clades including S, V, and G. Studies have demonstrated that the C14408T and A23403G alterations in the Nsp12 and S proteins are the most prominent alterations in the world, leading to life-threatening mutations.The spike D614G amino acid change has become the most common variant since December 2019. From missense mutations found from Gujarat SARS-CoV-2 genomes, C28854T, deleterious mutation in the nucleocapsid (N) gene was significantly associated with patients' mortality. The other significant deleterious variant (G25563T) is found in patients located in Orf3a and has a potential role in viral pathogenesis.
Overall, researchers identified several SARS-CoV-2 variants changing clinical manifestations and increasing the transmissibility, morbidity, and mortality of COVID-19. This should be considered in current practice and interventions to combat the pandemic and prevent related morbidity and mortality.
2019 年 12 月,冠状病毒病-2019(SARS-CoV-2)在中国武汉开始了其向全球大流行的破坏性轨迹。从那时起,已经确定了几种 SARS-CoV-2 的变体。在本综述中,我们旨在描述 SARS-CoV-2 的不同变体,并探讨相关的发病率和死亡率。
通过系统搜索,利用 Scopus、PubMed、Web of Science 和 Science Direct 等在线数据库中的关键词,进行了一项系统综述,包括与 SARS-CoV-2 不同变体及其相关发病率和死亡率相关的当前证据。我们检索了所有相关的论文和报告,这些论文和报告均以英语发表,时间范围为 2019 年 12 月至 2020 年 9 月。
对已确定文章的审查表明,有三种主要的基因组变体,包括 A 型、B 型和 C 型。我们还确定了三个谱系,包括 S、V 和 G。研究表明,Nsp12 和 S 蛋白中的 C14408T 和 A23403G 改变是世界上最突出的改变,导致危及生命的突变。自 2019 年 12 月以来,刺突 D614G 氨基酸改变已成为最常见的变体。从古吉拉特邦 SARS-CoV-2 基因组中发现的错义突变中,核衣壳(N)基因中的 C28854T 有害突变与患者的死亡率显著相关。在 ORF3a 中发现的另一个重要的有害变体(G25563T)具有潜在的病毒发病机制作用。
总的来说,研究人员确定了几种 SARS-CoV-2 变体,这些变体改变了临床表现,并增加了 COVID-19 的传染性、发病率和死亡率。在当前的实践和干预措施中,应考虑这一点,以对抗大流行并预防相关的发病率和死亡率。